Literature DB >> 19881895

Inconsistency of the MLE for the Joint Distribution of Interval-Censored Survival Times and Continuous Marks.

Marloes H Maathuis1, Jon A Wellner.   

Abstract

This paper considers the non-parametric maximum likelihood estimator (MLE) for the joint distribution function of an interval-censored survival time and a continuous mark variable. We provide a new explicit formula for the MLE in this problem. We use this formula and the mark-specific cumulative hazard function of Huang & Louis (1998) to obtain the almost sure limit of the MLE. This result leads to necessary and sufficient conditions for consistency of the MLE, which imply that the MLE is inconsistent in general. We show that the inconsistency can be repaired by discretizing the marks. Our theoretical results are supported by simulations.

Year:  2008        PMID: 19881895      PMCID: PMC2770882          DOI: 10.1111/j.1467-9469.2007.00568.x

Source DB:  PubMed          Journal:  Scand Stat Theory Appl        ISSN: 0303-6898            Impact factor:   1.396


  6 in total

1.  A note on inconsistency of NPMLE of the distribution function from left truncated and case I interval censored data.

Authors:  W Pan; R Chappell
Journal:  Lifetime Data Anal       Date:  1999-09       Impact factor: 1.588

2.  Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation.

Authors:  M G Hudgens; G A Satten; I M Longini
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

3.  Maximum likelihood estimation of ordered multinomial parameters.

Authors:  Nicholas P Jewell; John D Kalbfleisch
Journal:  Biostatistics       Date:  2004-04       Impact factor: 5.899

4.  Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable.

Authors:  Michael G Hudgens; Marloes H Maathuis; Peter B Gilbert
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

5.  CURRENT STATUS DATA WITH COMPETING RISKS: LIMITING DISTRIBUTION OF THE MLE.

Authors:  Piet Groeneboom; Marloes H Maathuis; Jon A Wellner
Journal:  Ann Stat       Date:  2008-01-01       Impact factor: 4.028

6.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

  6 in total
  1 in total

1.  Toward computerized efficient estimation in infinite-dimensional models.

Authors:  Marco Carone; Alexander R Luedtke; Mark J van der Laan
Journal:  J Am Stat Assoc       Date:  2018-09-13       Impact factor: 5.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.